Thermo Fisher Scientific Capabilities Update July 2026: Fill/Finish

If you're working with high-value biologics, antibody-drug conjugates (ADCs), or personalized medicines, you already know the pressure of limited drug substance availability. What you might underestimate is how much your yield outcomes are shaped before a single GMP batch runs. Decisions made during development strategy and tech transfer, not just on the manufacturing floor, can dramatically affect how much of that scarce material you actually get to the finish line.

This presentation from Thermo Fisher Scientific's team walks through practical examples from real sterile development programs. The core argument: as clinical batch sizes shrink and drug substances become more constrained and costly, material utilization has to be treated as a first-class concern from the earliest stages of your program. That means being strategic with limited drug substance during development, thinking carefully about process design and product presentation factors like stability, and making technology and operating model decisions well ahead of GMP entry.

The framing here is refreshingly operational rather than theoretical. Watch the full presentation to see specific examples of how early-stage choices translate into measurable yield impact in GMP manufacturing.